Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.

Jones HM, Zhang Z, Jasper P, Luo H, Avery LB, King LE, Neubert H, Barton HA, Betts AM, Webster R.

CPT Pharmacometrics Syst Pharmacol. 2019 Oct;8(10):738-747. doi: 10.1002/psp4.12461. Epub 2019 Sep 23.

2.
3.

Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.

Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, Zhang M, Cunningham O, Jones R, Fennell BJ, McDonnell B, Sakorafas P, Apgar J, Finlay WJ, Lin L, Bloom L, O'Hara DM.

MAbs. 2018 Feb/Mar;10(2):244-255. doi: 10.1080/19420862.2017.1417718. Epub 2018 Jan 29.

4.

Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.

Piche-Nicholas NM, Avery LB, King AC, Kavosi M, Wang M, O'Hara DM, Tchistiakova L, Katragadda M.

MAbs. 2018 Jan;10(1):81-94. doi: 10.1080/19420862.2017.1389355. Epub 2017 Nov 3.

5.

Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, Hua F, Jones HM, Neubert H, Polzer RJ, O'Hara DM.

MAbs. 2016 Aug-Sep;8(6):1064-78. doi: 10.1080/19420862.2016.1193660. Epub 2016 May 27.

6.

Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.

Fan YY, Avery LB, Wang M, O'Hara DM, Leung S, Neubert H.

MAbs. 2016 Jul;8(5):848-53. doi: 10.1080/19420862.2016.1178436. Epub 2016 Apr 22.

7.

Pharmacological activation of myosin II paralogs to correct cell mechanics defects.

Surcel A, Ng WP, West-Foyle H, Zhu Q, Ren Y, Avery LB, Krenc AK, Meyers DJ, Rock RS, Anders RA, Freel Meyers CL, Robinson DN.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1428-33. doi: 10.1073/pnas.1412592112. Epub 2015 Jan 20.

8.

A selective phenelzine analogue inhibitor of histone demethylase LSD1.

Prusevich P, Kalin JH, Ming SA, Basso M, Givens J, Li X, Hu J, Taylor MS, Cieniewicz AM, Hsiao PY, Huang R, Roberson H, Adejola N, Avery LB, Casero RA Jr, Taverna SD, Qian J, Tackett AJ, Ratan RR, McDonald OG, Feinberg AP, Cole PA.

ACS Chem Biol. 2014 Jun 20;9(6):1284-93. doi: 10.1021/cb500018s. Epub 2014 Apr 7.

9.
10.

Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain.

Kelly KM, Beck SE, Metcalf Pate KA, Queen SE, Dorsey JL, Adams RJ, Avery LB, Hubbard W, Tarwater PM, Mankowski JL.

AIDS. 2013 Nov 28;27(18):F21-8. doi: 10.1097/QAD.0000000000000074.

11.

Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.

Lade JM, Avery LB, Bumpus NN.

Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79. doi: 10.1128/AAC.01401-13. Epub 2013 Aug 5.

12.

Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect.

Avery LB, Zarr MA, Bakshi RP, Siliciano RF, Hendrix CW.

AIDS Res Hum Retroviruses. 2013 Nov;29(11):1434-42. doi: 10.1089/AID.2013.0031. Epub 2013 May 22.

13.

Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.

Avery LB, Sacktor N, McArthur JC, Hendrix CW.

Antimicrob Agents Chemother. 2013 Mar;57(3):1409-14. doi: 10.1128/AAC.02329-12. Epub 2013 Jan 7. Erratum in: Antimicrob Agents Chemother. 2013 Aug;57(8):4095.

14.

Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.

Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN.

Drug Metab Dispos. 2013 Feb;41(2):422-9. doi: 10.1124/dmd.112.049601. Epub 2012 Nov 19.

15.

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Tovar-y-Romo LB, Bumpus NN, Pomerantz D, Avery LB, Sacktor N, McArthur JC, Haughey NJ.

J Pharmacol Exp Ther. 2012 Dec;343(3):696-703. doi: 10.1124/jpet.112.195701. Epub 2012 Sep 13.

16.

The male genital tract is not a pharmacological sanctuary from efavirenz.

Avery LB, Bakshi RP, Cao YJ, Hendrix CW.

Clin Pharmacol Ther. 2011 Jul;90(1):151-6. doi: 10.1038/clpt.2011.99. Epub 2011 Jun 1.

17.

A highly sensitive ultra performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) technique for quantitation of protein free and bound efavirenz (EFV) in human seminal and blood plasma.

Avery LB, Parsons TL, Meyers DJ, Hubbard WC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Dec 1;878(31):3217-24. doi: 10.1016/j.jchromb.2010.09.011. Epub 2010 Oct 8.

Supplemental Content

Loading ...
Support Center